Navigation Links
Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
Date:3/17/2008

SALT LAKE CITY, March 17 /PRNewswire/ -- Axial Biotech, Inc., a company revolutionizing spine care through the development of molecular diagnostics and motion preserving technologies, announced today that it has met several major scientific milestones in its development of the first genetic prognostic test for Adolescent Idiopathic Scoliosis (AIS) and has closed a $6 million tranche of its Series B financing. The Series B financing was led by Johnson & Johnson Development Corporation, with participation by vSpring Capital and Ohio Biotech Group.

"These scientific milestones were extremely rigorous," said Kenneth Ward, M.D., the Chairman and Chief Scientific Officer of Axial Biotech. "They required our scientific team to analyze data from thousands of individuals and to confirm the identity of specific genetic markers that predict curve progression in early stage AIS with an extraordinary degree of accuracy, sensitivity, and specificity."

"I am very pleased about our team's accomplishments and for the continued support of our investors," said John M. Climaco, Axial Biotech's President and CEO. "For surgeons, patients, and their families, the significance of a genetic prognostic test for AIS, which can discriminate between progressive and non-progressive cases of the disease, is difficult to overestimate. It will positively impact the lives of thousands of children and should provide a springboard for the development of future scoliosis treatment options and may include the use of the company's motion preserving technologies."

"Axial Biotech's achievement of these very challenging milestones represents one of the largest steps in the company's efforts to bring important diagnostic tools to the orthopedic clinic," stated Dinesh Patel, Managing Director, vSpring Capital. "Our latest investment can be viewed as a clear vote of confidence, in the role that molecular diagnostics will play, in advancing the treatment of spinal disorders."

Axial Biotech is the first company to pursue DNA-based predictive tests for common spinal conditions. In addition to its groundbreaking work with AIS, Axial Biotech has also initiated clinical studies in the development of genetic tests for other common spinal diseases. Axial Biotech expects to launch its genetic prognostic test for AIS in September, 2008.

About Axial Biotech, Inc.

Axial Biotech, Inc. is a privately held, venture-backed company founded in 2002 by a group of internationally recognized spine surgeons and geneticists. The company is focused on developing and commercializing DNA-based pre-symptomatic and prognostic tests, as well as motion-preserving technologies, for common spinal disorders. The company's headquarters and laboratory are located in Salt Lake City, Utah.

About Johnson & Johnson Development Corporation.

Organized in 1973, Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC makes private equity investments in venture funded health care companies. Portfolio companies include those in the fields of pharmaceuticals, biotechnology, medical devices, diagnostics, and consumer products.

About vSpring Capital

vSpring Capital (http://www.vspring.com) is an early-stage venture capital firm with $350 million under management. With offices in Utah, New Mexico and Colorado, vSpring invests in information technology and life science companies that have the potential to transform their markets and create lasting value.

About Ohio Biotech Group

Ohio Biotech Group is a group of angel investors that include some of the leading spine surgeons in the United States.


'/>"/>
SOURCE Axial Biotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting
2. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
4. A Communitys Fight to Preserve its Historical and Rural Culture in Virginia: Biotechnology CEO Gets Involved
5. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
6. Biotechnology Leader to Exhibit at Upcoming Trade Show
7. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
8. New Books on Best Practices in Biotechnology Business Development and Biotechnology Education
9. Tunnell Consulting Expands Biotechnology Expertise
10. Biotech Drops Amid Tough Markets in February
11. Genetic Engineering & Biotechnology News reports on advances in miRNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... 06, 2016 , ... The Center for Excellence in Education (CEE) will sponsor ... on Wednesday February 10, 2016. This Bite of Science session, hosted by the ... at 1500 Remount Road in Front Royal, VA from 5:00 p.m. to 8:00 p.m. ...
(Date:2/5/2016)... 2016  In the pharmaceutical industry the medical affairs ... launch activities including the identification and engagement of key ... especially high in the oncology therapeutic area where most ... the Role of Medical Affairs in Oncology Launch Excellence ... therapies find better ways to utilize medical affairs to ...
(Date:2/5/2016)... 5, 2016 Australian-US drug discovery and development company, ... appointment of a new Chairman, Mr John O,Connor , ... immediately. James Garner , has also been ... former Acting CEO, Mr Iain Ross , will resume ... --> James Garner , has also been formally appointed ...
(Date:2/4/2016)... , Feb. 4, 2016  Sangamo BioSciences, Inc. ... editing, announced today that Edward Lanphier , Sangamo,s ... on the progress of Sangamo,s ZFP Therapeutic ® ... strategy at 2:40 pm ET on Thursday, February 11, ... Global Healthcare Conference. The conference is being held in ...
Breaking Biology Technology:
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
Breaking Biology News(10 mins):